Acute Coronary Syndromes (ACS)Discovery2NCT07822581
"Discovery2" Study of Using MCG at Emergency Departments
An observational study of Acute Coronary Syndromes (ACS) and Coronary Artery Disease (CAD), run by SB Technology, Inc. at 1 site in United States.
Trial summary
The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain
- What is being tested?
- Magnetocardiography
- Type of treatment
- Medical device
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2026to 30 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients in the ED presenting with symptoms suggestive of acute coronary syndromes, with a HEART Score of 4 or above, and after the first ECG and troponin results have been obtained to rule-out STEMI or obvious non-ACS are potential candidates for this study. This represents the "grey-zone", suspected non-ST-elevation acute coronary syndrome (NSTE-ACS) patient population that is time-consuming to triage and often creates a bottleneck in the ED.
Who may be able to join
- Women and men aged 22 years and older
- Participant presenting with signs and symptoms suggestive of NSTE-ACS
- In ED chest pain/NSTE-ACS care pathway
- HEART Score 4+
- Have received their first troponin result and can accommodate an MCG scan before the second troponin result.
Who cannot join
- Unable to provide informed consent
- ST elevation myocardial infarction (STEMI)
- Active arrhythmia (as seen on the most recent ECG) such as atrial fibrillation, atrial flutter, ventricular tachycardia
- Acute hemodynamic instability
- Inability to lie supine and still for 5-10 minutes
- Known or suspected pregnancy
Show all 13Show fewer
- Unable or unwilling to comply with required follow-up
- Metallic passive implants that would make the participant unsuitable for MCG (e.g. spinal implants, metal shoulder replacements, dental implants.. etc.)
- Active implantable medical devices (e.g. pacemakers, neurostimulators.. etc.)
- Active illegal drug use per history of present illness
- Contraindicated for temporary removal of telemetry during MCG scan
- Clear non-ischemic cause for symptoms (e.g. trauma, viral infection, valve disease)
- Clinical conditions that in the opinion of the Investigator would compromise the safety of the participant or ability to complete the protocol (e.g., exceeds bed weight limit, allergy to adhesives)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UCSF - Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California, 94143
Katherine Steineman, 707-718-3130, katherine.steineman@ucsf.edu
Lucas Zier, MD, MS
About this study
Official title: "Discovery2" Study of Using Magnetocardiography (MCG) at Emergency Departments
The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain.
- Conditions
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
- Being tested
- Magnetocardiography
- Keywords
- Magnetocardiography (MCG)
- Medical subject headings
- Acute Coronary Syndrome, Coronary Artery Disease, Chest Pain, Non-ST Elevated Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MagnetocardiographyDevice
The SandboxAQ CardiAQ System is an investigational device, and it is intended to non-invasively measure and display the magnetic signals produced by the electric currents in the heart. Its purpose is to assist in the evaluation of myocardial ischemia and infarction risks, in patients with symptoms suggestive of ACS. It is intended to complement clinical judgment and to augment standard of care diagnostic tools.
What is being measured
The primary outcome is the main question the study is designed to answer.
Training machine learning algorithms.
The main objective of the study is to collect MCG and other clinical data from the intended patient population for training machine learning algorithms to identify the presence of High Risk - Coronary Artery Disease (HRCAD).
Measured: Up to 30 Days
Secondary outcomes (1)
Changes in MCG over time
The second objective is to characterize changes in MCG, if any, over the course of a patient's evaluation workflow in the ED, with a repeat MCG scan.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion28 Feb 2027 (estimated)
- Study completion30 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary Syndromes (ACS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SB Technology, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kit Yee Au-Yeung, PhD, Study director, SB Technology, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07822581
- Sponsor's protocol ID
- SB-ACS-006
- Acronym
- Discovery2
- Status last verified
- Aug 2026
- First submitted
- 1 Sep 2026
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Discovery2" Study of Using Magnetocardiography (MCG) at Emergency Departments
- ClinicalTrials.gov ID
- NCT07822581
- Acronym / sponsor ID
- Discovery2 / SB-ACS-006
- Conditions
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
- Keywords
- Magnetocardiography (MCG)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- SB Technology, Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 30 Mar 2027 (estimated)
- First posted
- 16 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients in the ED presenting with symptoms suggestive of acute coronary syndromes, with a HEART Score of 4 or above, and after the first ECG and troponin results have been obtained to rule-out STEMI or obvious non-ACS are potential candidates for this study. This represents the "grey-zone", suspected non-ST-elevation acute coronary syndrome (NSTE-ACS) patient population that is time-consuming to triage and often creates a bottleneck in the ED.
Key inclusion criteria (5 listed)
- Women and men aged 22 years and older
- Participant presenting with signs and symptoms suggestive of NSTE-ACS
- In ED chest pain/NSTE-ACS care pathway
- HEART Score 4+
- Have received their first troponin result and can accommodate an MCG scan before the second troponin result.
Key exclusion criteria (13 listed)
- Unable to provide informed consent
- ST elevation myocardial infarction (STEMI)
- Active arrhythmia (as seen on the most recent ECG) such as atrial fibrillation, atrial flutter, ventricular tachycardia
- Acute hemodynamic instability
- Inability to lie supine and still for 5-10 minutes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MagnetocardiographyThe SandboxAQ CardiAQ System is an investigational device, and it is intended to non-invasively measure and display the magnetic signals produced by the electric currents in the heart. Its purpose is to assist in the evaluation of myocardial ischemia and infarction risks, in patients with symptoms suggestive of ACS. It is intended to complement clinical judgment and to augment standard of care diagnostic tools. | Device | – |
Primary outcome
Training machine learning algorithms.
Time frame: Up to 30 Days
The main objective of the study is to collect MCG and other clinical data from the intended patient population for training machine learning algorithms to identify the presence of High Risk - Coronary Artery Disease (HRCAD).
1 secondary outcome
Changes in MCG over time
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Coronary Syndromes (ACS)
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
RecruitingPhase 4
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Not yet recruitingPhase 3
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kit Yee Au-Yeung, PhD study director
SB Technology, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndromes (ACS) and Coronary Artery Disease (CAD), run by SB Technology, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maggie LeDang (408-981-8754, clinical-trials@sandboxquantum.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Training machine learning algorithms. (time frame: Up to 30 Days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.